Hai Phong currently has 20 hospitals with 3,500 beds, 9 professional centers of medical colleges, 1 secondary medical school and 2 companies with 5,711 health cadres in which medical doctors: 974, professor: 4 phylosophy doctor: 6; masters of science: 9, 1st grade medical doctor: 329 and 2nd grade medical doctor: 133. The long term stratery of Hai Phong health branch aims at redution of the morbidity and mortality rate of the microbial and parasitological infections, gradual improvement the nutritional condition, assure of the standards of the food safety and hygience and enhancement of the health care services
Health ; Hospitals, Satellite

The low-density lipoprotein cholesterol (LDL-C) is established as a causative agent of atherosclerotic cardiovascular disease (ASCVD) and lowering plasma LDL-C levels represents the main approach to reduce the risk of cardiovascular events. Statins remain the cornerstone of drug therapy for dyslipidemia. Although moderate- to high- intensity statin therapy has demonstrated consistent benefits for secondary prevention of cardiovascular events, statin monotherapy is insufficient to achieve the guideline-recommended LDL-C levels for high- and very high-risk patients. Some patients cannot tolerate statins, especially when taking long-term high doses. Several non-statin drugs that have a complementary mechanism of action to statins are now available, including ezetimibe, monoclonal antibodies targeted to proprotein convertase subtilisin/kexin type 9 (PCSK9 mAb), and, more recently, inclisiran, bempedoic acid, and evinacumab. Considering the recommendations from guidelines by domestic and international cardiovascular associations, combining these drugs should be contemplated to attain treatment goals for patients.